Autopsy report · NCT00383487

A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer

“Extreme toxicity”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 6 months after it had already started.
• Ran for about 2 years 4 months before it stopped.
• 20 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Stanford University

Sponsor type

University, hospital or other

Conditions

Prostatic Neoplasms; Prostate Cancer

Interventions

Calcitriol; Naproxen-n-butyl nitrate

Participants

20

Sites

1

Countries

United States

Trials that died the same way

• Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients With Head and Neck Cancer
  “toxicity” (89% match in meaning)
• Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer
  “Inadequate toxicity” (84% match in meaning)
• CPX-351+GO in Subjects 55 Years Old, or Older, With AML
  “Dose limiting toxicities.” (70% match in meaning)
• Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma
  “Extreme toxicity in Phase I, study did not proceed to Phase II” (68% match in meaning)
• A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer
  “Dose limiting toxicity at the lowest planned dose level.” (65% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.